Fahire Goknur Akarca, MD

Pathology and Laboratory Medicine
Call 800-789-7366
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Pathology and Laboratory Medicine

My education and training

  • Medical School: Ankara University

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Akarca is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Fahire Goknur Akarca, Sanjay Kakar Gastrointestinal Pathology and Liver Metastasis - Book Chapter: Metastatic Small Intestinal Well-differentiated NET vs HCC vs Other neoplasms. , Gastrointestinal Pathology and Liver Metastasis, no volume(no issue): 2025,691-698

Fahire Goknur Akarca, Sanjay Kakar Gastrointestinal Pathology and Liver Metastasis - Book Chapter: Metastatic Anorectal Melanoma vs Primary/Metastatic Tumors. , Gastrointestinal Pathology and Liver Metastasis, no volume(no issue): 2025,716-719

Akarca FG, Grenert JP, Kakar S. Role of genomic analysis in the classification of well differentiated hepatocellular lesions , Hum Pathol, 158(no issue): 2025,105794

Akarca FG, Shaheen NJ, Stachler MD. Does radiofrequency ablation of the lower oesophagus allow for clonal expansion of highly mutated neosquamous epithelium? , BMJ Oncol, 2(1): 2023,e000089

Akarca FG, Yozu M, Alpert L, Kővári BP, Zhao L, Salomao M, Liao X, Westerhoff M, Lauwers GY, Choi WT. Non-conventional dysplasia is frequently associated with low-grade tubuloglandular and mucinous adenocarcinomas in inflammatory bowel disease , Histopathology, 83(2): 2023,276-285

Nikka Khorsandi, Fahire Goknur Akarca, Kwun Wah Wen Inflammatory cloacogenic polyp , Pathology Outlines: 2023

Fahire Goknur Akarca, Nikka Khorsandi, Kwun Wah Wen Anal Fistula , Pathology Outlines: 2022

Redston M, Noffsinger A, Kim A, Akarca FG, Rara M, Stapleton D, Nowden L, Lash R, Bass AJ, Stachler MD. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia , Gastroenterology, 162(2): 2022,468-481

de Klerk LK, Patel AK, Derks S, Pectasides E, Augustin J, Uduman M, Raman N, Akarca FG, McCleary NJ, Cleary JM, Rubinson DA, Clark JW, Fitzpatrick B, Brais LK, Cavanaugh ME, Rode AJ, Jean MG, Lizotte PH, Nazzaro MJ, Severgnini M, Zheng H, Fuchs CS, Enzinger PC, Bass AJ. Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival , J Immunother Cancer, 9(9): 2021,e002472

Wu Z, Zhou J, Zhang X, Zhang Z, Xie Y, Liu JB, Ho ZV, Panda A, Qiu X, Cejas P, Cañadas I, Akarca FG, McFarland JM, Nagaraja AK, Goss LB, Kesten N, Si L, Lim K, Liu Y, Zhang Y, Baek JY, Liu Y, Patil DT, Katz JP, Hai J, Bao C, Stachler M, Qi J, Ishizuka JJ, Nakagawa H, Rustgi AK, Wong KK, Meyerson M, Barbie DA, Brown M, Long H, Bass AJ. Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence , Nat Genet, 53(6): 2021,881-894